Yes, The Good Doctor, Dr. Christopher Missling in one of his more recent online utterances made a tangential but significant anticipation of blarcamesine eventually being broadly taken like aspirin, to stop or prevent various diseases.
Of course, that, too, was the statement of Dr. Randi Hagerman, who runs clinical trials of blarcamesine in real humans. She said that she, too, would like to take it for prophylactic purposes, to obviate various aging debilities.
Should that happen, ponder what would happen to Anavex Life Sciences Corp. Aspirin, acetylsalicylic acid, had its origins as the salycylic acid in willow tree bark. Clever chemists at the Bayer Pharmaceuticals hung an acetyl group on the molecule, learned how to mass produce it, and aspirin made the company.
In 1897, scientists at the drug and dye firm Bayer began investigating acetylsalicylic acid as a less-irritating replacement for standard common salicylate medicines, and identified a new way to synthesize it. By 1899, Bayer had dubbed this drug Aspirin and was selling it around the world. https://en.wikipedia.org/wiki/History_of_aspirin
Blarcamesine will be Anavex's aspirin. Anavex will become a major global pharmaceutical.
And some of us have stock ownership that we hold for the many good years to ensue. An eventual AVXL share price of $1249 is not out of the question, at all.
News 
Market Data 
Discover 
